Weight Loss Medication Study (Phase 3 Clinical Trial)

Now Enrolling in Valparaiso and Vestal

Now Enrolling

About this research study

Obesity is associated with an increased risk of developing type 2 diabetes (T2D), hypertension, cardiovascular (CV) disease, obstructive sleep apnea, and many other medical conditions. Losing weight with lifestyle changes can be difficult to maintain long term, and weight-loss surgeries can present with major risks.

Velocity is now seeking participants for an investigational weight loss medication study in conjunction with lifestyle changes.

Eligible participants...

  • Must be age 18 or older
  • Must have either: 1) a BMI of at least 30 kg/m2 OR 2) have a BMI at least 27 kg/m2 the presence of at least two weight-related comorbidities, such as hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or prediabetes
  • Must have previously attempted to lose weight unsuccessfully
  • Compensation for time and travel may be provided
  • Do not need insurance to join this study

For more information, complete the form on this page. After you submit your information, a Velocity enrollment specialist will call you to talk about the study. There is no obligation to participate — you can decide if the study is right for you.

Enter your info

Study Locations

Valparaiso, Indiana • Velocity Clinical Research

55 University Drive, Suite 106, Valparaiso, IN 46383
Phone: (219) 464-8302

Vestal, New York • Velocity Clinical Research

4100 Vestal Road, Ste LL-100, Vestal, NY 13850
Phone: (607) 794-5790

©2023 Velocity Clinical Research | All Rights Reserved | Privacy Policy